Sameshima Tomoya, Miyahisa Ikuo, Homma Misaki, Aikawa Katsuji, Hixon Mark S, Matsui Junji
Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan.
Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan; Enzymology and Biophysical Chemistry, Takeda California, Inc., 10410 Science Center Drive, San Diego, CA 92121, United States.
Bioorg Med Chem Lett. 2014 Dec 15;24(24):5836-5839. doi: 10.1016/j.bmcl.2014.09.073. Epub 2014 Oct 2.
Identification of inhibitors for protein-protein interactions (PPIs) from high-throughput screening (HTS) is challenging due to the weak affinity of primary hits. We present a hit validation strategy of PPI inhibitors using quantitative ligand displacement assay. From an HTS for Bcl-xL/Mcl-1 inhibitors, we obtained a hit candidate, I1, which potentially forms a reactive Michael acceptor, I2, inhibiting Bcl-xL/Mcl-1 through covalent modification. We confirmed rapid reversible and competitive binding of I1 with a probe peptide, suggesting non-covalent binding. The advantages of our approach over biophysical assays include; simplicity, higher throughput, low protein consumption and universal application to PPIs including insoluble membrane proteins.
由于初次筛选出的活性化合物亲和力较弱,通过高通量筛选(HTS)鉴定蛋白质-蛋白质相互作用(PPI)的抑制剂具有挑战性。我们提出了一种使用定量配体置换测定法对PPI抑制剂进行活性验证的策略。从针对Bcl-xL/Mcl-1抑制剂的高通量筛选中,我们获得了一个活性候选物I1,它可能形成一种反应性迈克尔受体I2,通过共价修饰抑制Bcl-xL/Mcl-1。我们证实了I1与探针肽的快速可逆和竞争性结合,表明存在非共价结合。我们的方法相对于生物物理测定法的优势包括:简单、高通量、低蛋白消耗以及普遍适用于包括不溶性膜蛋白在内的PPI。